ENLIVEN THERAPEUTICS INC: MIZUHO INCREASES TARGET PRICE FROM $41 TO $45
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ELVN?
Source: moomoo
- Price Increase Announcement: Mizuhō raises the target price for Enlivex Therapeutics from $41 to $45.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the therapeutic sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.830
Low
35.00
Averages
40.67
High
48.00
Current: 38.830
Low
35.00
Averages
40.67
High
48.00
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helen Collins Sells 40,000 Shares of Enliven Therapeutics
- Transaction Overview: Helen Louise Collins exercised and sold 40,000 shares of Common Stock between March 9-10, 2026, generating approximately $1.20 million at a weighted average price of $30.07 per share, reducing her direct holdings by 61.54% from 65,000 to 25,000 shares.
- Market Reaction Analysis: Following Collins' sale, Enliven Therapeutics' stock closed at $30.24 on March 10, 2026, indicating positive market sentiment towards the company's future potential, despite Collins selling at a lower price than the subsequent market value.
- Clinical Progress and Competition: Enliven Therapeutics focuses on developing small-molecule therapies for cancer, with its CML candidate ELVN-001 showing a 47% major molecular response rate at 24 weeks, although Merck's acquisition of Terns Pharmaceuticals may spark interest in acquiring Enliven.
- Investor Caution: Despite Enliven Therapeutics' potential in the biotech sector, the Motley Fool Stock Advisor analyst team did not include it in their current list of top investment stocks, advising investors to carefully consider market dynamics before making investment decisions.
See More
Enliven's CMO Exercises and Sells Stock Options for $1.2 Million
- Stock Option Exercise: Helen Louise Collins, CMO of Enliven Therapeutics, exercised 40,000 stock options and immediately sold them for approximately $1.2 million, reflecting her liquidity management strategy.
- Shareholding Stability: Following the transaction, Collins's direct common stock holdings remained unchanged at 25,000 shares, indicating her continued confidence in the company's future prospects.
- Market Performance: As of March 27, 2026, Enliven's stock closed at $38.83, approximately 28.5% higher than the average sale price reported by Collins, highlighting market recognition of the company's potential value.
- Clinical Advancements: Enliven is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-mutant cancers, both in clinical trials, showcasing its competitive edge in the precision oncology space.
See More
Enliven's CMO Sells 40,000 Shares for $1.2 Million
- Stock Option Exercise: Helen Louise Collins, CMO of Enliven Therapeutics, exercised 40,000 stock options and immediately sold them for approximately $1.2 million, indicating a strategic focus on liquidity management.
- Ownership Stability: Following the transaction, Collins's direct common stock holdings remained unchanged at 25,000 shares, reflecting her sustained confidence in the company's future prospects.
- Market Performance: As of March 27, 2026, Enliven's stock closed at $38.83, approximately 28.5% higher than the average sale price reported by Collins, showcasing positive market sentiment towards the company.
- Clinical Progress: Enliven is developing ELVN-001 for chronic myeloid leukemia, with recent reports indicating a significant molecular response in 47% of patients treated at 24 weeks, bolstering investor confidence in its future potential.
See More
Terns Acquisition Sparks Hope for Enliven Therapeutics' Blood Cancer Pipeline
Enliven's ELVN-001: Enliven's ELVN-001 is a promising investigational therapy for chronic myeloid leukemia (CML), offering a complementary mechanism to Novartis's TERN-701, with analysts viewing it as a lower-risk, high-upside asset.
Clinical Trials and Development: The late-stage ENABLER-2 trial for ELVN-001 is on track for the second half of 2026, pending FDA alignment on dose selection and trial design.
Merck's Acquisition: Merck has entered a definitive agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion, highlighting the growing interest in CML therapies.
Market Sentiment: Following the acquisition news, Enliven's stock saw a 15% rally, with retail sentiment shifting from neutral to bullish, and the stock gaining 68% over the past year.
See More
ENLIVEN THERAPEUTICS INC: MIZUHO INCREASES TARGET PRICE FROM $41 TO $45
- Price Increase Announcement: Mizuhō raises the target price for Enlivex Therapeutics from $41 to $45.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the therapeutic sector.
See More
Enliven Therapeutics (ELVN.US) Officer Plans to Sell $3.08 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Patel Anish plans to sell 100,000 shares of Enliven Therapeutics (ELVN.US) on March 24, with an estimated market value of approximately $3.08 million.
Reduction in Shareholding: Anish has reduced his shareholding in Enliven Therapeutics by 48,300 shares since January 9, 2026, with a total value of around $1.35 million.
See More
Helen Collins Sells 40,000 Shares of Enliven Therapeutics
- Transaction Overview: Helen Louise Collins exercised and sold 40,000 shares of Common Stock between March 9-10, 2026, generating approximately $1.20 million at a weighted average price of $30.07 per share, reducing her direct holdings by 61.54% from 65,000 to 25,000 shares.
- Market Reaction Analysis: Following Collins' sale, Enliven Therapeutics' stock closed at $30.24 on March 10, 2026, indicating positive market sentiment towards the company's future potential, despite Collins selling at a lower price than the subsequent market value.
- Clinical Progress and Competition: Enliven Therapeutics focuses on developing small-molecule therapies for cancer, with its CML candidate ELVN-001 showing a 47% major molecular response rate at 24 weeks, although Merck's acquisition of Terns Pharmaceuticals may spark interest in acquiring Enliven.
- Investor Caution: Despite Enliven Therapeutics' potential in the biotech sector, the Motley Fool Stock Advisor analyst team did not include it in their current list of top investment stocks, advising investors to carefully consider market dynamics before making investment decisions.
See More
Enliven's CMO Exercises and Sells Stock Options for $1.2 Million
- Stock Option Exercise: Helen Louise Collins, CMO of Enliven Therapeutics, exercised 40,000 stock options and immediately sold them for approximately $1.2 million, reflecting her liquidity management strategy.
- Shareholding Stability: Following the transaction, Collins's direct common stock holdings remained unchanged at 25,000 shares, indicating her continued confidence in the company's future prospects.
- Market Performance: As of March 27, 2026, Enliven's stock closed at $38.83, approximately 28.5% higher than the average sale price reported by Collins, highlighting market recognition of the company's potential value.
- Clinical Advancements: Enliven is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-mutant cancers, both in clinical trials, showcasing its competitive edge in the precision oncology space.
See More
Enliven's CMO Sells 40,000 Shares for $1.2 Million
- Stock Option Exercise: Helen Louise Collins, CMO of Enliven Therapeutics, exercised 40,000 stock options and immediately sold them for approximately $1.2 million, indicating a strategic focus on liquidity management.
- Ownership Stability: Following the transaction, Collins's direct common stock holdings remained unchanged at 25,000 shares, reflecting her sustained confidence in the company's future prospects.
- Market Performance: As of March 27, 2026, Enliven's stock closed at $38.83, approximately 28.5% higher than the average sale price reported by Collins, showcasing positive market sentiment towards the company.
- Clinical Progress: Enliven is developing ELVN-001 for chronic myeloid leukemia, with recent reports indicating a significant molecular response in 47% of patients treated at 24 weeks, bolstering investor confidence in its future potential.
See More
Terns Acquisition Sparks Hope for Enliven Therapeutics' Blood Cancer Pipeline
Enliven's ELVN-001: Enliven's ELVN-001 is a promising investigational therapy for chronic myeloid leukemia (CML), offering a complementary mechanism to Novartis's TERN-701, with analysts viewing it as a lower-risk, high-upside asset.
Clinical Trials and Development: The late-stage ENABLER-2 trial for ELVN-001 is on track for the second half of 2026, pending FDA alignment on dose selection and trial design.
Merck's Acquisition: Merck has entered a definitive agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion, highlighting the growing interest in CML therapies.
Market Sentiment: Following the acquisition news, Enliven's stock saw a 15% rally, with retail sentiment shifting from neutral to bullish, and the stock gaining 68% over the past year.
See More
ENLIVEN THERAPEUTICS INC: MIZUHO INCREASES TARGET PRICE FROM $41 TO $45
- Price Increase Announcement: Mizuhō raises the target price for Enlivex Therapeutics from $41 to $45.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the therapeutic sector.
See More
Enliven Therapeutics (ELVN.US) Officer Plans to Sell $3.08 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Patel Anish plans to sell 100,000 shares of Enliven Therapeutics (ELVN.US) on March 24, with an estimated market value of approximately $3.08 million.
Reduction in Shareholding: Anish has reduced his shareholding in Enliven Therapeutics by 48,300 shares since January 9, 2026, with a total value of around $1.35 million.
See More
